The next generation of evidence-based medicine
- PMID: 36646803
- DOI: 10.1038/s41591-022-02160-z
The next generation of evidence-based medicine
Abstract
Recently, advances in wearable technologies, data science and machine learning have begun to transform evidence-based medicine, offering a tantalizing glimpse into a future of next-generation 'deep' medicine. Despite stunning advances in basic science and technology, clinical translations in major areas of medicine are lagging. While the COVID-19 pandemic exposed inherent systemic limitations of the clinical trial landscape, it also spurred some positive changes, including new trial designs and a shift toward a more patient-centric and intuitive evidence-generation system. In this Perspective, I share my heuristic vision of the future of clinical trials and evidence-based medicine.
© 2023. Springer Nature America, Inc.
References
-
- Ramsey, B. W., Nepom, G. T. & Lonial, S. Academic, foundation, and industry collaboration in finding new therapies. N. Engl. J. Med. 376, 1762–1769 (2017). - DOI
-
- Butler, D. Translational research: crossing the valley of death. Nature 453, 840–842 (2008). - DOI
-
- DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016). - DOI
-
- Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA 323, 844–853 (2020). - DOI
-
- Subbiah, V. A global effort to understand the riddles of COVID-19 and cancer. Nat. Cancer 1, 943–945 (2020). - DOI
Publication types
MeSH terms
Grants and funding
- R01CA242845/U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- R01CA273168/U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- P30 CA016672/CA/NCI NIH HHS/United States
- U01 CA180964/CA/NCI NIH HHS/United States
- UL1 TR000371/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical